Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

131.21
Delayed Data
As of Feb 24
 +9.26 / +7.59%
Today’s Change
60.30
Today|||52-Week Range
131.89
+30.86%
Year-to-Date
Here's Why Incyte Rose as Much as 8% Today
Feb 24 / MotleyFool.com - Paid Partner Content
Troubling Trial Data Weighed on Agenus Inc Stock Today
Feb 22 / MotleyFool.com - Paid Partner Content
Better Buy: Juno Therapeutics vs. Incyte
Feb 24 / MotleyFool.com - Paid Partner Content
What's Driving Lilly's (LLY) Shares after 2016 Decline?
Feb 16 / Zacks.com - Paid Partner Content
Biotech Movers: Cempra Flys High On Phase Three Results
Feb 24 / TheStreet.com - Paid Partner Content
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
Feb 15 / Zacks.com - Paid Partner Content
3 All-or-Nothing Stocks We're Closely Watching
Feb 23 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Present...
Feb 15 / Zacks.com - Paid Partner Content
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Bioscienc...
Feb 22 / GuruFocus News - Paid Partner Content
Why Agenus Stock Is Surging Today
Feb 14 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close121.95
Today’s open128.27
Day’s range127.56 - 131.89
Volume9,231,041
Average volume (3 months)1,465,724
Market cap$24.9B
Dividend yield--
Data as of 4:00pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)+1,700.00%
Earnings growth (this year)-5.06%
Earnings growth (next 5 years)+95.15%
Revenue growth (last year)+46.70%
P/E ratio166.1
Price/Sales17.60
Price/Book59.07

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc+0.30+0.56%
MYLMylan NV-0.17-0.40%
BAXBaxter International...+0.10+0.20%
VRTXVertex Pharmaceutica...+0.34+0.40%
Data as of 4:02pm ET, 02/24/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)-$0.67
Annual revenue (last year)$1.1B
Annual profit (last year)$104.2M
Net profit margin9.43%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts


Search for Jobs